The Indianapolis-based drugmaker said revenue increased 36% in the quarter, to $11.3 billion. Zepbound, the popular obesity drug that launched in December, crossed into blockbuster territory, with sales of $1.23 billion in the quarter.
Meanwhile, Lilly announced that Zepbound improved the long-term health of patients with obesity-related heart failure in a study.
Researchers reported Sunday that new blood tests were 91% accurate in detecting Alzheimer’s disease, far more accurate than a diagnosis from primary care doctors and specialists.
The spotlight is turning to Indianapolis-based Eli Lilly and Co. as the next possible member of the so-called “Trillion-Dollar Club,” based on the drugmaker’s climbing stock price and swelling demand for its treatments for diabetes, obesity and other diseases.
Shortages of brand-name drugs made by Novo and Eli Lilly and Co. have allowed pharmacies to make what are essentially copies, and telehealth companies like Hims are selling them to patients at a steep discount.
The Roche drug is a once-daily pill, compared to Lilly’s tirzepatide, sold under the brand names Mounjaro (for diabetes) and Zepbound (for obesity), which is a once-weekly shot.
Massachusetts-based Morphic Holding Inc. is a nine-year old, publicly traded company that is developing a class of drugs known as oral integrin therapies to treat autoimmune diseases, pulmonary hypertensive diseases, fibrotic diseases and cancer.
Eli Lilly and Co., Caitlin Clark and the Indiana Fever, the IUPUI split and other big stories have kept the newsroom busy in 2024.
Eli Lilly’s drug—Kisunla, the brand name for donanemab—is one of the few treatments developed for Alzheimer’s that modifies the underlying disease and will join just one other drug, Leqembi, on the commercial market.
The race to score blockbuster weight-loss drugs like Eli Lilly’s Mounjaro and Zepbound is pushing one of the world’s largest population of people with obesity to creative lengths.
The Indianapolis-based drugmaker said Thursday it was taking legal action against at least six additional medical spas and weight loss centers that it claimed are selling counterfeit and compounded versions of tirzepatide, the active ingredient in Lilly’s diabetes treatment Mounjaro and weight-loss treatment Zepbound.
At issue is whether a drug developed by Point Biopharma, based in Indianapolis, infringed on a patent issued in 2020 and assigned to Purdue Research Foundation.
If the FDA agrees with the panel’s recommendation, the drug, donanemab, would only be the second Alzheimer’s drug cleared in the U.S. that’s been shown to convincingly slow cognitive decline and memory problems due to Alzheimer’s.
Lilly officials have said they are “incredibly confident” in the drug’s potential and the fact that it “offers very meaningful benefits to people with early symptomatic Alzheimer’s disease.”
Anat Ashkenazi was Lilly’s third-highest paid executive last year. She has worked at the company for 23 years, including as chief financial officer since 2021.
If the guidance is confirmed, Mounjaro will challenge the dominance of Novo’s Wegovy in the United Kingdom.
Lilly plans to outfit its Lebanon plants—now under construction—with the latest in robotic, digital manufacturing equipment that will do much of the work that a generation ago was done by humans.
Eli Lilly and Co. plans to build the center on an existing parking lot at its downtown campus, with the goal of hosting more of its global meetings in Indianapolis.
Lilly said the new investment will allow it to hire 200 more workers at the complex, including engineers, scientists, and lab technicians, for a total of 900 full-time workers when it is fully operational.
The pharmaceutical weight-loss market is predicted to reach at least $100 billion by 2030, according to Goldman Sachs.
